AUTHORS
Catherine Thuy Khanh Le, MD, PhD, Caitlin Gribbin, MD2, David Bond, MD, BS3, Bijal Shah, MD, MS4, John N Allan, M.D.5, Sarah C Rutherford, MD6, Zhengming Chen7, Brittany Hobbie8, Melinda Harbhajan9, Erin Mulvey, MD10, Kami Maddocks, MD11, John Leonard, MD12, Peter Martin, FRCPC, MD, MS13, Jia Ruan, MD, PhD14
AFFILIATIONS
1 Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, United States
2 Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, United States
3 Division of Hematology, The Ohio State University, Columbus, Ohio, United States
4 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, United States
5 Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, United States
6 Department of Medicine at NYU Grossman School of Medicine, New York, New York, United States
7 Division of Biostatistics, Weill Cornell Medicine, New York, New York, United States
8 Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, United States
9 Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, United States
10 Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, United States
11 Division of Hematology, The Ohio State University, Columbus, Ohio, United States
12 Department of Medicine at NYU Grossman School of Medicine, New York, New York, United States
13 Department of Medicine at NYU Grossman School of Medicine, New York, New York, United States
14 Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, United States
ABSTRACT
BACKGROUND: Initial treatment for mantle cell lymphoma (MCL) has advanced with the incorporation of BTK inhibitors into chemoimmunotherapy and chemo-free novel regimens. We hypothesized that the combination of acalabrutinib (A), lenalidomide (L) and anti-CD20 antibody rituximab (R) or obinutuzumab (O) has therapeutic synergy to target both tumor cells and tumor microenvironment via BTK inhibition and T cell immunomodulation. Here we report long-term findings of the response-adapted and time-limited triplet treatment of ALR and ALO with a focus on longitudinal minimal residual disease (MRD).
METHODS: This study included induction and maintenance, with A provided at 100 mg BID continuously. L was administered at 15 mg daily during induction (cycles 1-12), with dose escalation to 20 mg if tolerated followed by reduction to 15 mg during maintenance. Cycle length was 28 days. For ALR (n=24), R was administered weekly x 4 during cycle 1, then every other cycle. For ALO (n=10), O was administered days 1, 8, and 15 during cycle 1, monthly for cycles 2-6, then once every other cycle for study duration. A+L could be discontinued after 24 cycles for subjects achieving an MRD-undetectable CR. All treatment could be discontinued after 36 cycles. The primary objective was MRD-undetectable (<10-6) CR rate at the conclusion of 12-cycle induction therapy. Secondary objectives included safety, response rates by Lugano criteria, and survival. MRD in peripheral blood was measured by Adaptive ClonoSEQ every 4-6 months for 5 years at sensitivity levels of 10-5 and 10-6.
RESULTS: The study met its accrual with 24 subjects enrolled for ALR and 10 for ALO. At study entry, median age was 64 years (range 35-82). The M:F ratio was 4:1. All patients had stage III/IV disease, 38% had elevated LDH, and 91% had bone marrow involvement. MIPI scores were 38% low-, 32% intermediate-, and 29% high-risk. Ki67 index was <30% in 65% subjects. TP53 mutations were detected in 29% of subjects. Treatment was associated with expected side effects (induction AE reported in Blood Adv 2026:10:1381). During maintenance, grade 3/4 hematologic toxicities included asymptomatic neutropenia (4/34, 12%), thrombocytopenia (1/34, 3%), and anemia (1/34, 3%). Most nonhematologic toxicities were grade 1/2, more common in induction than in maintenance. Nine incidences of secondary malignancies occurred, including 1 renal cell carcinoma requiring resection and 8 noninvasive skin cancers (6 nonmelanomatous, 2 melanoma in situ). In ALR (n=24), at a median follow-up of 65 months (range, 57-75), the ORR was 100% (90%CI, 88-100%) with a CR rate of 83% (90%CI, 66-94%). The 5-year OS and PFS for ALR were 92% (95%CI, 81-100%) and 74% (95%CI, 56-92%), respectively. For the subset patients with TP53 mutations (n=6), the 5-year OS and PFS were 83% (95%CI, 54-100%) and 50% (95%CI, 10-90%). In ALO (n=10), with median follow-up of 39 months (range 15-40), ORR and CR were 90% (95%CI, 61-100%), and 3-year OS and PFS were both 100% (95% CI, 100-100%). Seven ALR patients (29%) relapsed; 3 relapsed during maintenance and 4 after treatment completion. Relapses were all detected by MRD and imaging. All received subsequent treatment (2 with brexu-cel, 2 with acalabrutinib combination with either LR or O, 3 with pirtobrutinib combination) with a subsequent ORR of 86%. One patient with TP53 mutation progressed through 5 lines of subsequent treatment, including with brexu-cel and pirtobrutinib combination, and died from lymphoma. All ALO patients remain in remission. At 10-6 sensitivity, longitudinal MRD undetectable rates at 6, 12, 24, and 36 months were 12/24 (50%), 16/24 (67%), 17/22 (77%), and 15/20 (75%) for ALR and 8/9 (89%), 9/9 (100%), 8/8 (100%), and 8/8 (100%) for ALO, respectively. At 10-5 sensitivity, MRD undetectable rates at 6, 12, 24, and 36 months were 15/24 (63%), 18/24 (75%), 18/22 (82%), and 18/20 (90%) for ALR and 9/9 (100%), 9/9 (100%), 8/8 (100%), and 8/8 (100%) for ALO, respectively. MIPI score, Ki67 index, TP53 mutations, or MRD status were not significantly associated with survival.
CONCLUSIONS: Patients treated with ALO/ALR combination therapy continue to maintain durable long-term molecular responses on longitudinal MRD follow-up. This study demonstrates that the ALR/ALO regimen is feasible and effective as a time-limited initial therapy for patients with both TP53 wild type and mutant MCL, providing an alternative to BTKi + BCL2i regimens (ClinicalTrials.gov - NCT03863184).
DISCLOSURES
Catherine Thuy Khanh Le, MD, PhD: No relevant conflicts of interest to declare.